Pharmacokinetic, Safety and Tolerability Study of SPARC1028

This is a phase I study of SPARC1028 and recommend phase II dose of SPARC1028 administered
once a week for 3 weeks, followed by 1 week of rest.

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage
which taxane-based therapy is a rational treatment option.

- Age ≥18 years

- ECOG Performance Status ≤ 1.

- Estimated life expectancy of at least 12-weeks;

Exclusion Criteria:

- Any malignancy within past 5-years, except non-melanoma skin cancer, cervical
intraepithelial neoplasia, or in situ cervical cancer

- Known hypersensitivity to the study drugs

- Treatment with any anti-cancer agents within 28 days of study entry

- Presence of clinically evident active CNS metastases, including leptomeningeal
involvement, requiring steroid or radiation therapy